Glenmark's innovation arm develops new candidate for cancer treatment

image credit- freepik

Ichnos Glenmark Innovation, Inc. (IGI), Mumbai-based Glenmark Pharma's innovation arm, has announced a new development candidate, ISB 2301, a first-in-class, multispecific immune cells (T and NK) activator, for the potential treatment of multiple solid tumour indications.

ISB 2301 targets three tumour-associated antigens to trigger tumor cell death and engages both T cells and NK cells to ignite the immune system.

IGI designed ISB 2301 to induce potent antibody-dependent cellular cytotoxicity (ADCC), potent checkpoint inhibition, and a sustained type 1 immune response.  IGI’s proprietary BEAT^® technology enabled the development of this next-generation multispecific antibody, which can be manufactured with a standard multispecific antibody process. ISB 2301 demonstrates excellent pharmacokinetics, tolerability, and a favorable safety profile in non-human primates. IGI intends to file an IND submission by the end of this year and begin clinical studies in 2027.

“The early-stage clinical success of our prior lead investigational asset, ISB 2001, was a defining moment for IGI in that it attracted a collaboration with AbbVie, validating not just the science, but the platform behind it,” said Lida Pacaud, M.D., President and Chief Executive Officer (CEO). “It’s this same platform that provided the engineering capability to develop such a highly complex molecule as ISB 2301. We look forward to advancing ISB 2301 into clinical studies and exploring the potential of this novel therapeutic approach for cancer patients with solid tumors.”